Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy

Diabetes Research and Clinical Practice

Volumn 66, Issue 1, 2004, Pages 87-95

  Haneda, Masakazu ^a   Kikkawa, Ryuichi ^b   Sakai, Hideto ^c   Kawamori, Ryuzo ^d  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c TOKAI UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Candesartan; Proteinuria; Type 2 diabetes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIZZINESS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLACEBOS; POLYMORPHISM, GENETIC; PROTEINURIA; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 4444243476     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.02.015     Document Type: Article

References (20)

1. Statistic Committee of Japan Hemodialysis Society, An overview of dialysis treatment in Japan (as of 31 December 2001), J. Jpn. Soc. Dial. Ther. 36 (2003) 1-31.
2. UK Prospective Diabetes Study (UKPDS) Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes, Br. Med. J. 317 (1998) 703-713.
3. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of the HOPE study and MICRO-HOPE substudy, Lancet 355 (2000) 253-259.
4. Laffel L.M.B., et al. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am. J. Med. 99:1995;497-504
5. The Microalbuminuria Captopril Study Group, Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria, Diabetologia 39 (1996) 587-593.
6. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345:2001;861-869
7. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345:2001;851-860
8. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345:2001;870-878
9. Viberti G., Wheeldon N.M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Group Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood-pressure-independent effect. Circulation. 106:2002;672-678
10. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. 321:2000;1440-1444
11. Rossing K., Christensen P.K., Hansen B.V., Cartensen B., Parving H.H. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diab. Care. 26:2003;150-155
12. Weinberg M.S., Weinberg A.J., Cord R., Zappe D.H. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS. 2:2001;S196-S198
13. Apperloo A.J., de Zeeuw D., De Jong P.E. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 51:1997;793-797
14. Penno G., Chaturvedi N., Talmud P.J., et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 47:1998;1507-1511
15. Jacobsen P., Rossing K., Rossing P., et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 53:1998;1002-1006
16. Yoshida H., Mitarai T., Kawamura T., et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J. Clin. Invest. 96:1995;2162-2169
17. Dudley C.R., Keavney B., Stratton I.M., Turner R.C., Ratcliff P.J. UK Prospective Diabetes Study. XV: relationship of renin-angiotensin system gene polymorphism with microalbuminuria in NIDDM. Kidney Int. 48:1995;1907-1911
18. Andersen S., Tarnow L., Cambien F., et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype. Kidney Int. 62:2002;192-198
19. Andersen S., Tarnow L., Cambien F., et al. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype. Diab. Care. 26:2003;1501-1506
20. Kurokawa K., Abe K., Saruta T., et al. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. JRAAS. 3:2002;167-175